Comanche Biopharma closes oversubscribed $75 Million Series B financing to advance first treatment targeting a root cause of preeclampsia.
Comanche Biopharma, an siRNA biotech created by veterans of The Medicines Company, has reeled in a $75 million Series B to test its drug candidate for preeclampsia, a pregnancy complication that impacts millions of women each year.
CONCORD, Mass., Aug. 23, 2023 /PRNewswire/ -- Comanche Biopharma Corp. today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of CBP-4888 for the treatment of sFlt1-mediated pre-term preeclampsia. CBP-4888 is a subcutaneously delivered siRNA therapeutic that is currently in a Phase 1 clinical trial. The FDA’s Fast Track program is designed to facilitate the development, and expedite the review of, novel potential therapies that are designed to treat serious conditions and address an unmet medical need.
CONCORD, Mass., June 12, 2023 /PRNewswire/ -- Comanche Biopharma is pleased to announce the appointment of Ann Taylor, M.D. to its Board of Directors. Dr. Taylor brings a wealth of experience and expertise, having held academic positions at Harvard Medical School and key leadership roles at Pfizer, Novartis, and AstraZeneca.